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Molecular studies have shown that the majority of azole resistance in Aspergillus fumigatus is associated with
amino acid substitutions in the cyp51A gene. To obtain insight into azole resistance mutations, the cyp51A gene
of 130 resistant and 76 susceptible A. fumigatus isolates was sequenced. Out of 130 azole-resistant isolates, 105
contained a tandem repeat of 34 bp in the promoter region and a leucine-to-histidine substitution in codon 98
(designated TR/L98H). Additionally, in 12 of these TR/L98H resistant isolates, the mutations S297T and F495I
were found, and in 1 isolate, the mutation F495I was found. In eight azole-resistant isolates, known azole
resistance mutations were detected in codon G54, G138, or M220. In three azole-susceptible isolates, the
mutation E130D, L252L, or S400I was found and in 13 azole-susceptible isolates but also in 1 azole-resistant
isolate, the mutations F46Y, G98G, M172V, N248T, D255E, L358L, E427K, and C454C were found. All of the
nonsynonymous mutations, apart from the mutations in codons G54, G138, and M220 and L98H, were located
at the periphery of the protein, as determined by a structural model of the A. fumigatus Cyp51A protein, and
were predicted neither to interact with azole compounds nor to affect structural integrity. Therefore, this wide
diversity of mutations in the cyp51A gene in azole-susceptible A. fumigatus isolates is not correlated with azole
resistance. Based on the Cyp51A protein homology model, the potential correlation of a mutation to azole
resistance can be predicted.
Aspergillus fumigatus is the etiological agent of a range of
clinical syndromes, most notably invasive aspergillosis (IA),
which is associated with significant morbidity and mortality.
Advances in the management of IA have been made in recent
years by imaging techniques, by the use of non-culture-based
diagnostic tools, by improvement in the management of pa-
tients with IA, and by the use of more effective antifungal
agents, especially azole compounds (2). Azole resistance in
clinical A. fumigatus isolates has long been considered to be an
uncommon phenomenon, but recently multiazole resistance
(MAR) has been reported to be emerging and is increasingly
recognized as a cause of treatment failure (7, 18, 23). Resis-
tance significantly complicates patient management, given the
limited number of alternative agents with evidence-based effi-
cacy in Aspergillus diseases and the fact that the azoles are the
only class of antifungal drugs that can be administered orally.
Azoles bind, with one of the nitrogen atoms of the azole ring,
to the iron atom of the heme group located in the center of the
Cyp51 protein and thereby probably block the access of lanos-
terol to the active site, where C14 is demethylated (24). This
leads to the substitution of methylated sterols and ergosterol
depletion in the fungal cell membrane, as well as to the accu-
mulation of toxic sterol intermediates that eventually causes
inhibition of fungal cell growth (19). Molecular studies have
shown that in the majority of cases azole resistance in A.
fumigatus is associated with mutations in the azole drug target
enzyme encoded by the cyp51A gene. This has been described
for azole-resistant A. fumigatus clinical isolates, as well as for
laboratory-induced azole-resistant A. fumigatus mutants (5).
Mutations at codon G54 are related to cross-resistance to the
azoles itraconazole and posaconazole (4). Also, different mu-
tations in codon M220 have been described in clinical strains
that are correlated with itraconazole resistance combined with
different patterns of elevated MICs of the other azole drugs
(12). Azole-resistant A. fumigatus isolates have been found that
showed a glycine-to-cysteine substitution in codon 138 and
exhibited a pan-azole resistance phenotype (8). In codon 488,
a mutation from glycine to serine was correlated with resis-
tance to voriconazole and itraconazole (1). A recent survey of
MAR clinical isolates in the Netherlands showed over 90%
dominance of a resistance mechanism consisting of a tan-
dem repeat of 34 bp in the promoter region combined with
a leucine-to-histidine substitution at codon 98 (TR/L98H)
(11, 17, 18, 20, 23).
The cyp51A sequence of Mycobacterium tuberculosis shows
28% sequence identity over 464 residues with the cyp51A se-
quence of A. fumigatus. Therefore, it was possible to derive the
structure of the wild-type CYP51A protein of A. fumigatus
from the crystal structure of M. tuberculosis by homology mod-
eling (6, 26). The carefully optimized and checked structure of
the protein was used to characterize the mutations in the
CYP51A homology model. Two ligand access channels were
previously identified in the model which probably not only
accommodate the natural substrates but are also used by the
azole compounds for docking (6, 26). The aims of our study
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were to obtain insight into the distribution of mutations in the
cyp51A gene and to correlate the presence of cyp51A mutations
with the phenotype regarding their susceptibility to azole com-
pounds by using the Cyp51A protein homology model.
MATERIALS AND METHODS
The Department of Medical Microbiology of the Radboud University Nijme-
gen Medical Center has a policy of routinely storing all Aspergillus isolates
cultured from clinical specimens, irrespective of their clinical significance. In
addition, Aspergillus species cultured from the indoor or outdoor hospital envi-
ronment or as part of research collaborations are stored.
For several research studies performed at our center, 2,925 A. fumigatus
isolates were screened for resistance to itraconazole by subculturing on Sab-
ouraud agar slants that contained 4 or 8 mg/liter itraconazole. For isolates that
grew on itraconazole-containing agar (ITZ), the in vitro activities of ampho-
tericin B, itraconazole, voriconazole, posaconazole, and caspofungin were deter-
mined by using the Clinical and Laboratory Standards Institute M38-A reference
method (13). For classification of the MICs, the recently proposed interpretative
breakpoints were used (22). Isolates resistant to more than one azole compound
but not all of them were designated MAR, while isolates with MICs in the
resistant range for all clinically licensed mold-active azoles were designated
pan-azole resistant (22).
Of a total of 2,925 A. fumigatus isolates, 130 were able to grow on itraconazole-
containing agar. If resistance to itraconazole was confirmed, the cyp51A gene was
fully sequenced. From the isolates that failed to grow on itraconazole-containing
agar (ITZ), controls were selected. In total, 76 ITZ isolates were randomly
selected and matched on the basis of (i) the underlying disease of the patient, (ii)
the temporal relationship to an ITZ isolate, or (iii) the sample type (Fig. 1).
All isolates were identified to the A. fumigatus species level by macroscopic
and microscopic morphology, the ability to grow at 48°C, and sequencing of the
-tubulin gene. PCR amplification and subsequent sequencing of the -tubulin
gene were performed by using forward primer 5-AATTGGTGCCGCTTTCT
G-3 and reverse primer 5-AGTTGTCGGGACGGAATAG-3. Cycling and
sequencing conditions were the same as those described for the amplification of
the cyp51A gene. Sequences were compared with those of A. fumigatus, Aspergil-
lus lentulus, Aspergillus viridinutans, Aspergillus brevipes, Aspergillus novofumiga-
tus, Aspergillus fumigatiaffinis, and Neosartorya species, all obtained from the CBS
Fungal Biodiversity Center, Utrecht, Netherlands, by using the neighbor-joining
method for phylogenetic analysis (18). For selected isolates, the full sequence of
the cyp51A gene was determined. For this, conidia from each strain were inoc-
ulated into 15 ml of GYEP medium (2% glucose, 0.3% yeast extract, 1% pep-
tone) and grown for 48 h at 37°C. Mycelial mats were recovered, dried, and
subjected to a DNA isolation protocol as described previously (18). PCR ampli-
fication and subsequent sequencing of the cyp51A gene were performed by using
forward primer 5-ATGGTGCCGATGCTATGG-3 and reverse primer 5-CT
GTCTCACTTGGATGTG-3. Cycling conditions were as follows: 95°C for 5
min and 40 cycles of 94°C for 30 s, 58°C for 45 s, and 72°C for 2 min, followed
by a final extension at 72°C for 7 min. All DNA sequences were determined using
a BigDye Terminator version 3.1 cycle sequencing kit (ABI) and an ABI 3100
DNA sequencer. Sequences were aligned with a reference cyp51A sequence
(GenBank accession no. AF338659) to identify mutations.
A homology model of the A. fumigatus cyp51A gene was built using the crystal
structure of M. tuberculosis Cyp51A as a template (PDB code 1e9x). The two
proteins show 28% sequence identity over 464 residues. The WHAT IF web
server (http://swift.cmbi.ru.nl) was used for model building, and Yasara was used
for energy minimization and analysis. The structure was initially optimized in a
vacuum with all backbone atoms fixed. The locations of the mutations were
pinpointed, and they were introduced into the Cyp51A homology model by using
the VMD software (9). Furthermore, the mutations were investigated for their
potential interactions with azole compounds by considering the ligand binding
residues, the reported substrate access channel residues, and known mutation
hot spots (10, 26).
RESULTS AND DISCUSSION
A total of 206 A. fumigatus isolates, 130 ITZ and 76 ITZ,
were analyzed for mutations in the cyp51A gene. A wide variety
of mutations was found in the cyp51A gene of ITZ and ITZ
isolates, both known and not known from the literature to be
correlated with azole resistance (Table 1). In 113 ITZ iso-
lates, cyp51A mutations known to be correlated with azole
resistance were found. In 105 ITZ isolates, a tandem repeat
of 34 bp in the promoter region and a leucine-to-histidine
substitution at codon 98 (TR/L98H) were found, and in 8
ITZ isolates, other known mutations were found (11).
In 19 isolates that contained the TR/L98H mutations, addi-
tional mutations in the cyp51A gene (S297T, F495I, S52T,
Q88H, N125I, Q141H, A284A, and L339L) were found. In one
ITZ isolate, the mutations F46Y, G98G, M172V, N248T,
D255E, L358L, E427K, and C454C were found, and in 16
ITZ isolates, no mutations were found in the cyp51A gene. In
13 ITZ isolates, combinations of the mutations F46Y, G98G,
M172V, N248T, D255E, L358L, E427K, and C454C were
found, and in three ITZ the mutations, E130D, L252L, and
S400I were found. In 60 ITZ isolates, no mutations were
found in the cyp51A gene.
ITZ isolates. (i) Cyp51A mutations known to be correlated
with azole resistance. In eight ITZ isolates, mutations chang-
ing amino acid G54, G138, or M220 in the cyp51A-encoded
protein were detected (Table 1). These mutations were all
known to be correlated with azole resistance (4, 8, 12). The
amino acids in codons G54, G138, and M220 were all located
in close proximity to the opening of one of the two ligand
access channels of the protein (Fig. 2). The ligand access chan-
nels are thought to be used by the azole compounds to enter
the active site of the protein, and alterations of these openings
of these channels due to amino acid changes probably disturb
the docking of azole molecules. The G138C mutation was
FIG. 1. Procedure for selection of ITZ-resistant and -susceptible A.
fumigatus isolates for sequencing of the cyp51A gene.
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located in a helix of channel 1 close to the heme cofactor, and
isolates harboring this mutation show a pan-azole resistance
phenotype (Fig. 2). This was also described previously for
G138R, in which the arginine was predicted to clash with
one of the heme’s side chains and with the side chains of the
neighboring residues (26). Amino acids G54 and M220 are
located in loops in close proximity to the opening of channel
2. The M220R, -I, and -V mutations produced an itracon-
azole resistance phenotype combined with an increased
MIC of voriconazole, while M220K produced an itracon-
azole and posaconazole resistance phenotype. The mutation
G54W produced an itraconazole and posaconazole resis-
tance yet voriconazole susceptibility phenotype. As glycine
is replaced with the larger and hydrophobic tryptophan res-
idue, it might sufficiently close the entrance of access chan-
nel 2 to disturb the docking of large molecules such as those
of itraconazole and posaconazole. The long tails of itracon-
azole and posaconazole need to make interactions along the
opening and within the channel for stable docking toward the
heme center. The voriconazole molecule, however, is much
smaller than those of itraconazole and posaconazole since it
lacks a long tail. It does not need to make interactions at the
entrance surface of the channel. Therefore, changes in resi-
dues in codon 54, which is located at the entrance of the
channel, do not affect voriconazole but do have a dramatic
effect on the docking of itraconazole and posaconazole. Fur-
thermore, the G54E mutation produced only an itraconazole
resistance phenotype. The main difference in structure be-
tween posaconazole and itraconazole is the presence of the
hydroxyl group at the end of the long tail of posaconazole that
may create a hydrogen bond interaction on the surface of the
protein. Moreover, it is not clear whether an additional oxygen
atom in the core scaffold of itraconazole plays any role in
preventing the drug from accessing the active site in the pres-
ence of the G54E mutation. Therefore, not only the specific
location of an amino acid change is important but the amino
acid replacement is of at least the same importance for the
azole susceptibility phenotype. Although there are two ligand
TABLE 1. Mutations found in the cyp51A gene of A. fumigatus and azole susceptibility phenotypes
Phenotype and no. of
strains
MIC (range)a (g/ml)
Mutation(s) in cyp51A gene Source(s) (no.) ofisolate(s)ITZ VRC POS
ITZ (total n  130)
1 16 0.25 0.25 G54Eb Clinical
1 16 0.25 16 G54Wb Clinical
1 16 8 16 G138Cb Clinical
1 16 2 2 M220Rb Clinical
2 16 1 0.5 M220Ib Clinical
1 16 1 0.5 M220Vb Clinical
1 16 2 16 M220Kb Clinical
1 16 16 1 F46Y, G89G, M172V, N248T, D255E, L358L,
E427K, C454C
Clinical
12 16–16 1–4 0.063–0.25 TR,c L98H, S297T, F495I Clinical (11),
environmental (1)
1 16 2 0.125 TR, L98H, F495I Clinical
1 16 4 0.5 TR, L98H, S52T Environmental
1 16 8 0.25 TR, L98H, Q88H Clinical
1 16 8 0.5 TR, L98H, N125I Clinical
1 16 4 0.5 TR, L98H, Q141H Environmental
1 16 4 0.5 TR, L98H, A284A Clinical
1 16 8 1 TR, L98H, L339L Clinical
86 4–16 2–16 0.25–1 TR, L98H Clinical
16 8–16 0.25–4 0.125–16 None Clinical (13),
environmental (3)
ITZ (total n  76)
1 0.125 0.5 0.016 F46Y, G89G Clinical
1 0.25 0.25 0.063 F46Y, G89G, E427K, C454C Clinical
1 0.25 2 0.063 F46Y, G89G, L358L, E427K, C454C Clinical
1 0.25 1 0.125 F46Y, G89G, M172V, L358L, C454C Environmental
1 0.125 1 0.063 F46Y, M172V, L358L, E427K, C454C Clinical
5 0.125–0.5 0.5–1 0.063–0.125 F46Y, G89G, M172V, L358L, E427K, C454C Clinical (4),
environmental (1)
1 0.25 1 0.063 F46Y, G89G, M172V, N248T, D255E, E427K Clinical
2 0.25 0.25 0.063 F46Y, G89G, M172V, N248T, D255E, L358L,
E427K, C454C
Clinical
1 0.5 0.5 0.125 E130D Clinical
1 0.25 1 0.5 L252L Clinical
1 1 2 0.25 S400I Clinical
60 0.125 0.5 0.031 None Clinical (47),
environmental (13)
a Each isolate was tested once. When multiple isolates contain the same mutation, the MIC range is given. VRC, voriconazole; POS, posaconazole.
b Mutation known from the literature to be correlated with azole resistance.
c TR; tandem repeat of 34 bp in the promoter region of the cyp51A gene.
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access channels present, the change of an amino acid in the
opening in one channel is already sufficient for certain azole
resistance phenotypes. It seems that the structural changes in
one channel affect the docking of certain azole compounds for
the whole protein.
Out of 130 azole-resistant isolates, 105 contained the TR/
L98H mutations. It was shown that leucine 98 is not located
close to either the active heme center or any of the two ligand
access channels but is located on a loop that partly forms an
arch-like structure that is highly conserved among the mem-
bers of the CYP51 family of proteins (Fig. 2). In a preliminary
study, we have used molecular dynamic simulations changing
the leucine to histidine in codon 98. In these studies, we ob-
served that the flexibility of this arch-like structure increased
considerably, thereby narrowing the diameter of the entry of
the ligand access channels (data not shown). These changes
may result in the MAR phenotype by affecting the ligand
access channels important for the docking of azole compounds.
(ii) ITZ isolates with other cyp51A mutations. In each of
six isolates with the TR/L98H mutations, an additional muta-
tion was found, four nonsynonymous mutations, namely, S52T,
Q88H, N125I, and Q141H, and two synonymous mutations,
L339L and A284A (Table 1). Introduction of these mutations
into the CYP51A homology model showed that these muta-
tions were not located in conserved regions of the protein but
were all distributed on the periphery of the protein, except for
two, S52T and N125I (Fig. 2). S52 was located at the entrance
of channel 2; however, the serine is replaced with an only
slightly larger threonine that is similar to serine, an alcoholic
residue with intermediate hydrophobicity. The N125I mutation
represents a change from electrophilic asparagine to a large
nonpolar isoleucine and may have a larger impact on resis-
tance. However, as the isolates all contain the TR/L98H mu-
tations and exhibit the MAR phenotype, these additional non-
synonymous mutations probably play only a minor or no role at
all in the azole resistance phenotype and no differences in MIC
values were observed between these isolates and those con-
taining only the TR/L98H mutations. It is important to corre-
late changes in the structural integrity of the protein with
susceptibility to azole compounds because structural changes
could affect the docking of the azole molecules, with azole
resistance as a possible consequence. The amino acid residues
on the periphery of the protein generally have a lower conser-
vation level and are not essential for the functionality of the
protein; therefore, amino acid changes in these residues will
not influence structural integrity. The structural integrity of
the Cyp51A protein is not changed by the two synonymous
mutations L339L and A284A, since the amino acids are not
changed. However, the possibility of changes at the RNA
structural level due to silent mutations cannot be excluded, as
synonymous mutations in RNA regulatory elements might al-
ter transcription, splicing, and other regulatory processes, al-
though there is no evidence that they may actually play a role
in A. fumigatus (21, 25).
In 12 isolates with the TR/L98H mutations, the nonsynony-
mous mutations S297T and F495I were found, and in 1 isolate
with the TR/L98H mutations, only the F495I mutation was
found (Table 1). Interestingly, although both mutations are
located close to the active site of the protein, they do not seem
to affect resistance, as the TR/L98H mutations already pro-
duce the MAR phenotype and no differences in MIC values
were observed between these isolates and those containing
only the TR/L98H mutations. Apart from that, although threo-
nine is slightly larger than serine and both residues contain a
hydroxyl group, in the case of the second observed mutation,
F495I, the hydrophobic phenylalanine is replaced with a hy-
drophobic though not aromatic isoleucine. The slight differ-
ences are not expected to influence the binding of the external
ligands, and therefore these additional mutations do not seem
to affect protein function either (brown, Fig. 2).
(iii) ITZ isolates without cyp51A mutations. In 16 azole-
resistant isolates, no mutations were found in the cyp51A gene.
Azole-resistant A. fumigatus isolates without mutations in the
cyp51A gene have been reported previously in the literature,
FIG. 2. Mapping of mutations found in the A. fumigatus cyp51A gene in the CYP51A homology model. The two ligand access channels are
indicated by arrows. The heme cofactor is black. Mutations correlated with azole resistance are purple, and mutations correlated with an
azole-susceptible profile are green. Mutations additionally found in azole-resistant strains are brown.
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which suggests that alternative mechanisms of azole resistance
exist (7). The upregulation of efflux pumps has been described
as a mechanism of azole resistance in Candida albicans previ-
ously; however, for clinical A. fumigatus strains, this possibility
has only been described once (3, 16). A selection of two of
these ITZ isolates did not show any significant increase in the
mRNA expression levels of the ABC transporter AtrF or the
multidrug resistance protein MDR3 or MDR4 compared to
ITZ isolates (unpublished observations). Therefore, in these
isolates, an as-yet-unknown mechanism of azole resistance
must be present. Possibly, the cyp51A gene could be upregu-
lated, although no changes in the promoter region of the
cyp51A gene were present. Further investigation is warranted
to characterize the alternative mechanisms of resistance in
these isolates.
ITZ isolates. In 60 of 76 azole-susceptible isolates, no mu-
tations were found in the cyp51A gene. However, in 3 suscep-
tible isolates, either the nonsynonymous mutation E130D or
S400I or the synonymous mutation L252L was found. E130D
and S400I are both located on the periphery of the protein and,
indeed, do not seem to interact with azole compounds. Also, in
different combinations, five nonsynonymous mutations, F46Y,
M172V, N248T, D255E, and E427K, and three synonymous
mutations, G98G, L358L, and C454C, were found in 13 azole-
susceptible isolates. These mutations were also found in one
azole-resistant isolate without any other known mutation in the
cyp51A gene related to azole resistance. These exact same
mutations have been described previously in the literature to
be found in both azole-resistant and -susceptible isolates (7,
14). Therefore, amino acid changes found in the protein en-
coded by the cyp51A gene are not exclusively correlated with
the development of azole resistance. Introducing the nonsyn-
onymous amino acid alterations in the CYP51A homology
model shows that these amino acid changes are all distributed
at the periphery of the protein, not close to any of the two
ligand access channels (Fig. 2), and are not located in any of
the conserved regions of the CYP51A protein. Therefore, no
effect on the biological activity of the CYP51A protein or the
docking of the azole compounds in the ligand access channels
is expected.
Due to the importance of CYP51 in antifungal drug studies,
many CYP51 homology models have been made, e.g., C. albi-
cans, Cryptococcus neoformans, Penicillium digitatum, and Sac-
charomyces cerevisiae, by using the crystal structure of M. tu-
berculosis CYP51 as a template (10, 15, 26, 27). Although this
approach has several limitations, functionally important re-
gions are conserved among the members of this fungal CYP51
family. A wide diversity of amino acid changes probably not
correlated with resistance has been described by others (7, 14).
In this study, we showed that the use of a CYP51A homology
model can be very informative in predicting the effects of these
amino acid changes. Specific residues in the CYP51A protein
are of importance for azole docking, and identifying the loca-
tion of a mutation in the CYP51A protein can help to predict
whether a mutation can be considered a polymorphism or
whether it has a potential correlation with azole resistance.
Taking into account the diversity of cyp51A mutations, new
mutations found in the cyp51A gene in azole-resistant isolates
should be interpreted with care. By using a CYP51A protein
homology model, a mutation can be investigated for a corre-
lation with azole resistance. Subsequently, by placing the mu-
tation into a wild-type strain by recombinant analysis, the im-
pact of a mutation can be studied at the protein level to make
a conclusive correlation with azole resistance.
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